Barclays Maintains Equal-Weight on Moderna, Raises Price Target to $48

Benzinga Newsdesk www.benzinga.com Positive 72.8%

Neg 0% Neu 0% Pos 72.8%

Barclays analyst Eliana Merle maintains Moderna (NASDAQ:MRNA) with a Equal-Weight and raises the price target from $25 to $48.